• Encompass Health reported past second-quarter 2026 results with net operating revenue of US$1,597.4 million and net income of US$153.9 million, alongside higher earnings per share versus a year earlier.
• The company also raised its full-year 2026 revenue guidance and completed a long-running share repurchase program that has retired nearly one-tenth of its shares.
• We’ll now examine how Encompass Health’s raised 2026 revenue guidance shapes its investment narrative and what it may mean for investors.

Find 51 companies with promising cash flow potential yet trading below their fair value.

What Is Encompass Health's Investment Narrative?

To own Encompass Health, you really have to believe in the resilience of its inpatient rehabilitation model, disciplined capital allocation and the ability to steadily grow within a slower‑growing corner of healthcare. The latest quarter, with higher revenue, earnings and a lift to 2026 revenue guidance, reinforces that story and supports near‑term catalysts around execution on new hospital openings, pricing, and operating efficiency. The completion of a buyback retiring nearly one‑tenth of shares, together with increased repurchase authorization and a higher dividend, tilts the narrative more toward shareholder returns in the short run, which could matter if growth expectations remain moderate. On the risk side, a higher debt load after the new 2034 notes and index removal may matter more now, especially if funding conditions tighten or sentiment toward smaller healthcare names softens.

However, rising debt and index exclusion introduce funding and liquidity considerations that investors should not ignore. Encompass Health's shares have been on the rise but are still potentially undervalued by 22%. Find out what it's worth.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span roughly US$99 to about US$160 per share, underscoring how differently private investors price Encompass Health. Set against the recent guidance upgrade and heavier reliance on debt funding, this spread highlights why it can be useful to weigh multiple viewpoints before deciding how the company’s execution and balance sheet might influence future performance.

Explore 4 other fair value estimates on Encompass Health - why the stock might be worth 21% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Encompass Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Encompass Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Encompass Health's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.